Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Uti-Zen is a veterinary nutritional supplement developed by Nextmune and marketed under the Dermoscent brand to support urinary tract health in companion animals, specifically dogs and cats. The product is formulated as palatable, breakable oral tablets containing cranberry powder (*Vaccinium macrocarpon*) as the primary active ingredient. It is designed to support urinary comfort and well-being, particularly in elderly or stressed animals prone to urinary discomfort. The mechanism of action involves the properties of cranberry proanthocyanidins, which help limit the adhesion of *Escherichia coli* bacteria to the urinary tract wall and provide antioxidant effects. It has been commercially available since 2010 and is recommended for continuous, regular use to achieve optimal results.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Uti-Zen.